Genetic Mechanisms Contribute to the Development of Heart Failure in Patients with Atrioventricular Block and Right Ventricular Apical Pacing

Nana Liu¹, Min Zheng¹,², Shijie Li¹, Hui Bai¹, Zhouying Liu¹, Cui hong Hou¹, Shu Zhang¹ & Jielin Pu¹,²

Right ventricular apical (RVA) pacing can lead to progressive left ventricular dysfunction and heart failure (HF), even in patients with normal cardiac structure and function. Our study conducted candidate gene screening and lentivirus transfected neonatal rat cardiomyocytes (NRCMs) to explore the genetic and pathogenic mechanisms of RVA pacing induced cardiomyopathy in third degree atrioventricular block (III AVB) patients. We followed 887 III AVB patients with baseline normal cardiac function and RVA pacing. After a median follow-up of 2.5 years, 10 patients (four males, mean age 47.6 ± 10.0 years) were diagnosed with RVA pacing induced HF with left ventricular ejection fraction (LVEF) reducing dramatically to 37.8 ± 7.1% (P < 0.05). Candidate genes sequencing found cardiomyopathy associated genetic variations in all ten HF patients and six SCN5A variations in 6 of 20 control patients. Transfected NRCMs of Lamin A/C mutations (R216C and L379F) disrupted Lamin A/C location on nucleus membrane and finally resulted in increased apoptotic rate after serum starvation. In conclusion, cardiomyopathy associated genetic variations play an essential role in occurrence of newly onset HF in the III AVB patients with RVA pacing. RVA pacing, serving as extra stimulator, might accelerate the deterioration of cardiac structure and function.

As the only effective therapy for bradycardia, millions of permanent cardiac pacemakers are implanted worldwide every year. However, as previous studies have verified, right ventricular apical (RVA) pacing can cause electrical and mechanical dyssynchrony and eventually induce adverse effects on myocardial metabolism and perfusion, remodeling, hemodynamics and mechanical function¹,². Several large randomized controlled trials (RCTs) have confirmed the correlation between long-term RVA pacing and deterioration of heart structure and function, especially in patients with high RVA pacing burden and impaired baseline left ventricular ejection fraction (LVEF)³⁴. Usually, symptomatic patients with third degree atrioventricular block (III AVB) need high percentage of RVA pacing and are more liable to develop HF. Nowadays, based on the studies on AVB patients with normal or nearly normal baseline LVEF, the incidence of newly-onset HF induced by RVA pacing varies a lot, from 3.2% to 26%; and similar variation was found in the timing of onset, from 1 month to more than one decade, probably due to different recipient populations and follow-up durations⁵⁻¹⁴. There are several risk factors such as old age⁹,¹⁴, male gender¹¹, coronary artery disease⁹, wider native QRS duration (QRSd)¹¹,¹³ or wider paced QRSd⁹,¹² for RVA pacing cardiomyopathy.

The pathogenesis of HF involves a complex interaction between genetic and environmental factors. Genetic factors may influence the susceptibility to the underlying etiology of HF, the rapidity of disease progression, or the response to pharmacologic therapy¹⁵. Moreover, HF can arise in the setting of a primary cardiomyopathy, most commonly, dilated cardiomyopathy (DCM); 30–50% of DCM cases are familial aggregation and caused by genetic mutations¹⁶, among them Lamin A/C and TTN are the most common mutations detected in DCM cohort. Clinical studies have shown that Lamin A/C-DCM is characterized by early-onset atrial fibrillation and
conduction system disease, and subsequently, progression to HF and sudden cardiac death (SCD)\textsuperscript{17–19}. Thus, we hypothesize that genetic mechanism plays an important role in the development of newly-onset HF in certain III AVB patients and long-term RVA pacing may accelerate the deterioration of cardiac structure and function. To evaluate this hypothesis, we investigated the genetic background of III AVB patients with RVA pacing induced cardiomyopathy and explored the pathogenic mechanism with transfected neonatal rat cardiomyocytes (NRCMs).

### Results

#### Clinical characteristics of the study population.

877 patients were enrolled in our study. Before pacemaker implantation, all patients were diagnosed with third degree atrioventricular block (III AVB) for more than 3 months. Clinical characteristics of the study population are summarized in Table 1. The mean age was 57.4 ± 18.4 years, 465 (52.9%) were male. 408 (46.4%) patients were diagnosed with hypertension, 93 (10.6%) with hypercholesterol, 94 (10.7%) with Diabetes mellitus, 51 (5.8%) with coronary heart disease and 104 (11.8%) had a history of AF. Echocardiography showed the baseline LVEF (%) and LVEDD (mm) at the time of pacemaker implantation were 65.3 ± 7.9 and 50.0 ± 7.8. The baseline heart rate was 42 ± 12 bpm. There are no clear etiologies of III AVB in 693 (78.8%) cases, and the other 186 patients exhibited potential causes that may lead to III AVB. It was clear that cardiac surgery (64, 7.3%) was the most common cause. Among all the patients, 683 patients (75.7%) were designed to DDD pacing mode and 194 patients (22.1%) were with VVI mode.

#### Follow up

The whole population. After a median follow-up of 2.5 years, the average pacing percentage of the study population is 99.0%. Echocardiography showed the average LVEF of the whole population decreased significantly from 65.3 ± 7.9 to 60.7 ± 8.5 (\textit{p} < 0.001) and there was no significant change in LVEDD (mm, 50.0 ± 7.8 VS. 49.9 ± 6.8, \textit{p} = 0.748). In total, 31 (3.53%) were readmitted to Fuwai hospital because of refractory HF. The echocardiography of 31 patients showed significant decrease in LVEF (%), from 62.0 ± 5.6 to 35.9 ± 7.2, \textit{p} < 0.001 and increase in LVEDD (mm, from 54.0 ± 6.9 to 57.7 ± 7.6, \textit{p} = 0.014). Among the 31 newly-onset HF patients, 18 cases were found with MI, 2 with HCM and 1 with AF and rapid ventricular pacing according to the medical records. Ten patients with no alternative causes for HF were diagnosed as RVA pacing induced cardiomyopathy.

### Table 1. Baseline clinical characteristics of the study population. AF, Atrial Fibrillation; AVB, Atrioventricular Block, HCM, Hypertrophic Cardiomyopathy, HR, Heart Rate; LVNC, Left Ventricular Non-compaction Cardiomyopathy; RCM, Restricted Cardiomyopathy; RFA, Radiofrequency Ablation.

| Basic Characteristics          | n = 879 |
|-------------------------------|---------|
| Age (years)                   | 57.4 ± 18.4 |
| Male, n (%)                   | 465 (52.9) |
| Hypertension                  | 408 (46.4) |
| Hypercholesterol              | 93 (10.6) |
| Diabetes Mellitus             | 94 (10.7) |
| Coronary artery disease       | 51 (5.8) |
| History of AF, n (%)          | 104 (11.8) |
| Etiologies                    |         |
| None, n (%)                   | 693 (78.8) |
| Cardiac surgery               | 64 (7.3) |
| Cardiomyopathies, n (%)       | 26 (3.0) |
| HCM                           | 20 (2.3) |
| RCM                           | 5 (0.5) |
| LVNC                          | 1 (0.1) |
| Rheumatic heart disease       | 25 (2.8) |
| Myocardial infarction         | 24 (2.7) |
| Viral myocarditis             | 20 (2.3) |
| RFA                           | 15 (1.7) |
| Congenital third degree AVB   | 12 (1.4) |
| Baseline LVEF (%)             | 64.3 ± 7.1 |
| Baseline LVEDD (mm)           | 49.9 ± 6.8 |
| Baseline HR (bpm)             | 42 ± 12 |
| Pacing mode, n (%)            |         |
| DDD                           | 683 (75.7) |
| VDD                           | 20 (2.2) |
| VVI                           | 194 (22.1) |
| Mean percentage of ventricular pacing, (%) | 99.0 ± 2.3 |
Table 2. Clinical characteristics and genetic testing results of the HF patients. AVB, Atrioventricular Block; AF, Atrial Fibrillation; CLBBB, Complete Left Bundle Branch Block; LVEF, Left Ventricular Ejection Fraction; LVEDD, Left Ventricular End Diastolic Dimension; PVC, Premature Ventricular Contraction; HT, Hypertension; SCD, Sudden Cardiac Death; VT, Ventricular Tachycardia; VUS, Variation of Unknown Significance.

| Patients | Age/ Gender | Family History of SCD | Arrhythmias | Risk Factors | Pacing Mode | Baseline Echocardiography | Follow-up Echocardiography | Genetic Testing Results | Mutation Prediction |
|----------|------------|------------------------|-------------|--------------|-------------|--------------------------|---------------------------|------------------------|---------------------|
| 1        | 39/M       | Yes                    | III AVB, AF | HT           | VVI         | LVEF (%) 70 LVEDD (mm) 57 | Duration HF Onset (months) 28 | LVEF (%) 39 LVEDD (mm) 59 | LMNA p. Leu379Val | Pathogenic          |
| 2        | 41/M       | Yes                    | III AVB, AF, PVC, VT | None         | VVI         | LVEF (%) 63 LVEDD (mm) 56 | Duration HF Onset (months) 13 | LVEF (%) 31 LVEDD (mm) 65 | LMNA c.1157 +1 G > T | Pathogenic          |
| 3        | 57/M       | None                   | III AVB     | None         | DDD         | LVEF (%) 64 LVEDD (mm) 47 | Duration HF Onset (months) 12 | LVEF (%) 45.5 LVEDD (mm) 58 | TTN p. Gly565Asp; TTN p.Arg306Thr | Pathogenic; VUS |
| 4        | 37/F       | None                   | III AVB     | None         | DDD         | LVEF (%) 53 LVEDD (mm) 62 | Duration HF Onset (months) 15 | LVEF (%) 42.5 LVEDD (mm) 70 | DSP c.1140 +6 T > C | VUS                 |
| 5        | 54/F       | None                   | III AVB, PVC, VT, VF | None         | DDD         | LVEF (%) 62 LVEDD (mm) 55 | Duration HF Onset (months) 30 | LVEF (%) 25 LVEDD (mm) 64 | CACNA1C c.372:9C > G; CACNA1C c.4074 +6 C > T | VUS; VUS |
| 6        | 64/F       | Yes                    | III AVB, AF | HT           | DDD         | LVEF (%) 52 LVEDD (mm) 52 | Duration HF Onset (months) 25 | LVEF (%) 35.6 LVEDD (mm) 54 | LMNA p. Arg216Cys | Pathogenic          |
| 7        | 39/F       | None                   | III AVB     | None         | DDD         | LVEF (%) 60 LVEDD (mm) 57 | Duration HF Onset (months) 6 | LVEF (%) 39 LVEDD (mm) 59 | DSG2 p. Leu563Arg; AKAP9 c.9358 +10 A > G | VUS; VUS |
| 8        | 46/M       | None                   | III AVB, CLBBB | None         | DDD         | LVEF (%) 60 LVEDD (mm) 55 | Duration HF Onset (months) 28 | LVEF (%) 45 LVEDD (mm) 59 | TTR p. Ser43Asn; DSG2 p. Phe531Cys; CSRP1 p. Gly72Arg | Pathogenic; Pathogenic; Pathogenic |
| 9        | 60/F       | None                   | III AVB     | HT           | DDD         | LVEF (%) 63 LVEDD (mm) 47 | Duration HF Onset (months) 24 | LVEF (%) 28 LVEDD (mm) 61 | MYH7 p. Gly1902Gln; TTN p. Arg8985Cys | Pathogenic Pathogenic |
| 10       | 39/M       | None                   | III AVB     | None         | DDD         | LVEF (%) 54 LVEDD (mm) 54 | Duration HF Onset (months) 8 | LVEF (%) 42 LVEDD (mm) 58 | MYBPC3 p. Gly507Arg | Pathogenic |

RVP associated HF. Within 20.0 ± 10.2 months, all 10 cases (4 males, mean age of 47.6 ± 10.0 years) developed severe HF and were diagnosed with RVP induced HF. Compared with the baseline echocardiography, LVEF (%) reduced significantly from 60.1 ± 5.6 to 37.8 ± 7.1 (P < 0.05); meanwhile, LVEDD (mm) increased remarkably from 54.2 ± 4.9 to 61.0 ± 4.7 (P < 0.05). Nine of them were diagnosed as NYHA class II with one assigned to NYHA class III. Genetic testing revealed 15 cardiomyopathy associated genetic variations (10 pathogenic and 6 VUS) found in the 10 HF patients. Three patients with Lamin A/C variations (Lamin A/C p. Leu379Val, c.1157 +1 G > T and c.1157 +1 G > T) and one with MYBPC3 p. Gly507Arg mutations were found to have a family history of SCD. The Clinical characteristics and genetic results of HF patients are displayed in Table 2.

During the follow-up period, eight patients with RVP induced HF remained viable, while one (patient 2) died of SCD after contracting an upper respiratory infection and one (patient 10) died of chronic refractory HF. Twelve months of RVA pacing, the control group suffered nearly 5% decrease in LVEF (from 66.9 ± 5.6 to 61.6 ± 7.9%) compared to the HF group (% controls vs. HF, 66.9 ± 5.6 vs. 60.1 ± 5.6, P = 0.019), however mean LVEDD (controls vs. HF; 50.6 ± 5.6 mm vs. 54.2 ± 4.6 mm, P = 0.096) did not show any significant difference. After nearly 30 months of RVA pacing, the control group suffered nearly 5% decrease in LVEDD (from 66.9 ± 7.9% to 61.6 ± 5.7%, P < 0.01), but no one exhibited HF symptoms or LVEF below 50%. Meanwhile LVEDD did not significantly alter (baseline vs. follow-up, 50.7 ± 5.6 mm vs. 50.4 ± 4.7 mm; P = 0.807).

We did not detect any genetic mutations in 14 of the 20 controls. Six different loci variations of SCN5A were found in six patients. Of them, SCN5A p. Arg1193Gln was found uniquely or jointly with other SCN5A variations (p. Arg513Cys and c.10 C > T) and one with MYBPC3 p. Gly507Arg mutations were found to have a family history of SCD. The Clinical characteristics and genetic testing results of control group were listed in Table 3.

Characterizations of Lamin A/C mutations in NRCMs. To functionally characterize the newly identified Lamin A/C mutations, Neonatal rat cardiomyocytes (NRCMs) were transfected with lentiviruses of Lamin A/C WT and two mutations (R216C and L379 F). Fluorescence microscope was used to determine the nuclear localization. As expected, NRCMs expressing Lamin A/C WT showed regular rounded nucleus and Lamin A/C proteins demonstrated as small aggregates homogenously distributed in the nucleus; In contrast, Lamin A/C mutations had irregular nucleus, the localization of Lamin A/C proteins appeared profoundly impaired, clearly expressed in highlighted aggregates of different sizes, not uniformly distributed along the nuclear envelope (Fig. 1).
As patients with Lamin A/C mutations (R216C and L379F) developed III AVB before HF, we hypothesized whether defects in sodium channels and/or Connexin 43 (Cx43) accounted for the evolution of cardiac electrophysiological dysfunction. However, Western blot did not reveal any significant differences in the expression levels of Nav 1.5 and Cx43. On the other hand, compared with Lamin A/C WT, there were no significant differences in the location and expression of Cx43 or Nav1.5 in the nucleic membrane and cytomembrane of NRCMs of Lamin A/C mutations (Fig. 2).

**NRCMs apoptosis.** We hypothesized that progressive demise cardiomyocytes were responsible for the occurrence of AVB and HF. To further verify this hypothesis, we studied the apoptosis of normally cultured NRCMs and serum starved NRCMs. The serum starved NRCMs were cultured normally with 5% Fetal Bovine serum (FBS) within the first 72 hours and then cultured without FBS for 24 hours. 96 hours after lentiviruses transfection, cells specimens were fixed and examined for apoptosis by deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL). Compared with the normally cultured NRCMs, confocal imaging results showed there was no significant changes in the apoptotic rate in serum starved Lamin A/C WT cells (0.52% ± 0.33% vs. 1.03% ± 0.73%, n = 6, p = 0.109) Nevertheless, statistical increase in TUNEL positive cells were found in both Lamin A/C R216C cells (1.21% ± 0.44% vs. 6.64% ± 0.60%, n = 6, p < 0.05) and Lamin A/C L379F cells (0.68% ± 0.31% vs. 6.37% ± 0.97%, n = 6, < 0.05) after serum starvation (Fig. 3A,B). On the other hand, both Lamin A/C WT and mutations have similar apoptotic percentages under normal culture condition. However, there was no significant discrepancy in the expression level of activated caspase 3 under two different culture conditions (Fig. 3C), probably due to the relatively low percentage of apoptotic cells.

**Discussions**

Our results suggested that for some III AVB patients who developed RVA pacing induced HF, the cardiomyopathy associated genetic mutations account for conduction abnormality as well as ventricular enlargement and cardiac dysfunction. RVA pacing acting as extra stimulator may accelerate the process of deterioration of cardiac dysfunction. NRCMs carried Lamin A/C mutations (R216C and L379F) showed disrupted Lamin A/C nuclear location and increased apoptotic rate under environmental stress. Genetic testing contributes to the detection of patients with high risk of HF as well as exploration of the pathogenic mechanism.

Currently, there are still some conflicting results about the effects of RVA pacing in patients without heart failure. It was found that high percentage of RVA pacing was associated with HF hospitalization in some large RCT of PM9,20–22. However, some trials showed HF had nothing to do with RVA pacing23. Other risks such as older age, CAD and a wider paced QRS duration maybe associated with HF9,24. Importantly, it took a long term, usually more than three years, to manifest LV dysfunction in patients with baseline normal LVEF9,25,26. Furthermore, it has been shown that pacing location and sequence of cardiac electrical conduction have little effect on patients

### Table 3. Clinical characteristics and genetic testing results of the control group. AVB, Atrioventricular Block; AF, Atrial Fibrillation; LVEF, Left Ventricular Ejection Fraction; LVEDD, Left Ventricular End Diastolic Dimension; PVC, Premature Ventricular Contraction; HT, Hypertension.

| Patients | Age/ Gender | Arrhythmias | Risk Factors | Pacing Mode | Baseline Echocardiography | Follow-up Echocardiography | Genetic Testing Results |
|----------|-------------|-------------|--------------|-------------|---------------------------|----------------------------|------------------------|
|          |             |             |              |             | LVEF (%) | LVEDD (mm) | LVEF (%) | LVEDD (mm) |                          |
| 1        | 57/M        | III AVB, AF | None         | VVI         | 65       | 55         | 50       | 55         | SCN5A p. Lys590 Gln       |
| 2        | 41/M        | III AVB, AF | None         | VVI         | 52       | 58         | 50       | 49         | None                     |
| 3        | 37/M        | III AVB     | None         | DDD         | 63       | 44         | 61       | 50         | None                     |
| 4        | 64/F        | III AVB     | HT           | DDD         | 70       | 55         | 60       | 60         | None                     |
| 5        | 64/F        | III AVB     | HT           | DDD         | 66       | 58         | 59       | 55         | SCN5A p. Arg193 Gln       |
| 6        | 39/M        | III AVB     | None         | DDD         | 70       | 50         | 60       | 57         | SCN5A p. Arg193 Gln       |
| 7        | 34/F        | III AVB     | None         | DDD         | 67       | 43         | 63       | 40         | None                     |
| 8        | 39/F        | III AVB     | None         | DDD         | 76       | 60         | 65       | 53         | None                     |
| 9        | 34/F        | III AVB     | None         | DDD         | 50       | 50         | 60       | 47         | SCN5A p. Arg193 Gln; SCN5A c.2023 + 10 C>T |
| 10       | 64/F        | III AVB     | None         | DDD         | 65       | 55         | 67       | 53         | None                     |
| 11       | 64/F        | III AVB     | HT           | DDD         | 68       | 42         | 71       | 50         | SCN5A p. Arg193 Gln; SCN5A p. Arg113Gln |
| 12       | 39/M        | III AVB     | None         | DDD         | 77       | 59         | 70       | 53         | SCN5A p. Ala1126 Val      |
| 13       | 41/M        | III AVB     | None         | DDD         | 73       | 49         | 66       | 51         | None                     |
| 14       | 57/M        | III AVB, AF | DM           | VVI         | 64       | 52         | 60       | 54         | None                     |
| 15       | 39/M        | III AVB     | None         | DDD         | 79       | 51         | 60       | 49         | None                     |
| 16       | 39/F        | III AVB     | None         | DDD         | 65       | 48         | 53       | 46         | None                     |
| 17       | 60/F        | III AVB     | HT           | DDD         | 63       | 47         | 61       | 48         | None                     |
| 18       | 58/F        | III AVB     | None         | DDD         | 67       | 45         | 65       | 45         | None                     |
| 19       | 40/M        | III AVB, PVC| None         | DDD         | 63       | 47         | 64       | 47         | None                     |
| 20       | 42/M        | III AVB     | None         | DDD         | 68       | 45         | 66       | 46         | None                     |
with normal baseline LVEF in the Protect-Pace study\textsuperscript{27} and in a large Japanese study\textsuperscript{28}. Ruling out the risks of HF referred above, our study discovered that there were still a small amount of III AVB subjects of younger age (mean age, $47.1 \pm 10.0$ years) who developed new-onset HF within 3 years after PM implantation. This finding inspired us to explore other pathogenic mechanisms in the HF cases.

The major findings of this study revealed that for those who developed HF after RVA pacing, cardiomyopathy associated genetic mutations such as Lamin A/C mutations are the genetic background of conduction diseases and HF; RVA pacing could just be a coincidence, or a contributor. As the HF patients were diagnosed with AVB for more than three months, and HF occurred just after a short period of RVA pacing, it suggests pacing is the main inducement for HF. Cardiomyopathy associated genetic mutations play an essential role in the development of arrhythmias and finally progression to cardiac dysfunction. Wolf et al. showed that Lamin A/C haploinsufficiency led to early-onset programmed cell death of conducting cardiomyocytes such as atrioventricular nodal myocytes, and resulted in late-onset DCM and HF\textsuperscript{29}. Therefore, electrically active cardiomyocytes might be more likely to be destroyed, which led to heart block. According to two large studies about the genetic background of DCM\textsuperscript{16, 30}, there is a high percentage of overlap in the mutations causing DCM, HCM, ARVC and channelopathy. Remarkably, six cases in HF group carried compound or combined variations associated with DCM, HCM,
ARVC, or channelopathy and the overlapped phenotypes of AVB and HF could be explained by at least part of the above findings. Mutations associated with inherited arrhythmia and cardiomyopathy may result in both a destroyed conduction system and fragile cardiac walls, once PM is implanted, the fragile heart can be destroyed with increased burden of heartbeat rate.

We hypothesized that long-term RVA pacing could accelerate the deterioration of cardiac structure and function in cardiomyopathy mutation carriers. Multiple experimental studies using in-vivo pacing model or adult rat ventricular cardiomyocytes have demonstrated that rapid electrical pacing could induce increased mitochondrial activity and myocardial activation of Akt, JNK, Erk or p38 MAPK as well as abnormal Ca\(^{2+}\) homeostasis which correlated with the rise in cardiomyocytes apoptosis\(^{11, 31-34}\). Furthermore, Siu et al. found that Lamin A/C‐mutated iPSC-CMs showed markedly increased percentage of nuclear senescence and cellular apoptosis under field electrical stimulation\(^{35}\). In our study, Lamin A/C mutations (R216C and L379F) could significantly change the location of Lamin A/C proteins and affect nuclear mechanical stability. In addition, as the apoptotic rate did not show any difference in the normally cultured Lamin A/C WT and mutated NRCMs, only after serum starvation the percentage of apoptosis increased, which on the other hand means that mutated cells are more susceptible to the adverse effect of environmental stress. Once the HF cascade was activated, multiple factors such as electrical stimulators can accelerate the causal pathways. Furthermore, pharmacological blockade of apoptotic pathways of ERK1/2 or MEK 1/2 pathway, such as U0126 and selumetinib (AZD6244), significantly attenuated the pro-apoptotic effects of field electric stimulation on the mutated Lamin A/C iPSC-CMs\(^{35}\) and Lamin A/C -DCM mouse models\(^{36-38}\).

Four control patients carried the same SCN5A mutation p. Arg1193Gln. This mutation was initially found in a Japanese patient who survived sudden unexplained nocturnal death. Patch clamp recording showed this mutation could shift the balance of current towards \(I_{to}\) by accelerating the decay of \(I_{to}\)\(^{39}\). In addition, other studies in Han population found that this mutation was both a risk factor for LQTS\(^{40-42}\) and cardiac conduction defects\(^{42, 43}\). Without any signs of QTc elongation, our study adds more evidence of SCN5A p. Arg1139Gln being a genetic factor of cardiac conduction defects.

There were several risk factors discovered in the RVA induced HF patients, including family history of HF or SCD, younger age, combined brady/tachyarrhythmias, lower baseline LVEF and/or ventricular enlargement before PM implantation, rapid decrease of cardiac function after PM implantation, negative reaction to anti-HF drugs.

Figure 2. No significant differences on the location and expression of Nav1.5 or Cx43 between Lamin A/C WT and mutations. (A) Western blot showed equal expression level of Nav1.5 and Cx43; (B,C) Confocal imaging did not reveal significant difference on the expression either in nucleic membrane or in cytomembrane. ns, not significant.
Given the high proportion of genetic variants detected in the HF cohort, that genetic testing can be considered if it will help in counseling first-degree relatives. As several studies have shown that CRT preserves LVEF, minimizes LV dyssynchrony and prevents adverse remodeling in patients with normal LVEF. For those who carry pathogenic genetic mutations, maybe it is more sensible and effective to get biventricular pacing instead of right ventricular pacing at the first time of device implantation. Block-HF study has shown promising results of CRT on patients with third degree atrioventricular block and left ventricular systolic dysfunction. However, in our study, only one HF patient updated to CRT treatment. In the future, we can explore the application prospect of CRT in those with RVA pacing induced HF patients.

Study Limitations. This study has several limitations. Firstly, this was a retrospective study, and thus it cannot be excluded that patients with clinical heart failure obtained echocardiographic assessment more frequently and these patients were those with impending or subclinical laminopathy. Furthermore, our results came from a cohort from a single center in China, and did not account for genetic heterogeneity that is likely to be relevant when applied to other patient populations. Secondly, there were a limited number of controls underwent sequencing of candidate CMP genes and we failed to undergo cosegregation analysis of the SCN5A mutations identified in the control cohort. We evaluated their SNP frequencies and three databases (PolyPhen-2, SIFT and Mutation_Taster) were used to evaluate the function of SCN5A variations. Two mutations SCN5A p. Arg1139Gln and p. Ala1126Val have been shown to be pathogenic. However, other mutations (p. Lys590Gln, c.2023 + 10 C > T and p. Arg1126Cys) were VUS and pedigree validation was not available. In future study, we will perform more comprehensive genetic testing in a larger III AVB population to find more genetic evidence. Thirdly, specific pathogenic mechanisms of RVA pacing on the development of HF remains unclear and needs to be addressed by introduction of electrical field stimulation in transgenic animal models to explain the effect of RVA pacing on mutated cardiomyocytes. Fourthly, the hospitalization rate of newly-onset HF is 1.1% in our study, similar to it of Protect-Pace study, but lower than the HF rate of published randomized clinical trials. There are two reasons: for one, HF symptoms and signs are not specific for the diagnosis of HF. Some patients with mild HF symptoms are unaware of their pathogenic condition and some may just visit their local hospitals. Another reason, the average age in our study is 57.4 years old, which is much lower than those in RCTs (over 70 years old). Younger patients have less underlying diseases and are less likely to develop HF. Besides, most HF patients receive treatment in the outpatient clinic in our hospital, only those with severe HF symptoms and failed to respond to anti-HF drug therapy were hospitalized.

Figure 3. Apoptotic rate assessed by TUNEL and Western blot detection of activated caspase 3 in normally cultured and serum starved Lamin A/C NRCMs. (A) Confocal imaging of TUNEL assay showing normally cultured Lamin WT, R216C and L379 had similar apoptotic rate. However, Lamin A/C R216C and L379F with serum starvation had significantly increased apoptotic rate. (B) Quantification of apoptotic rate was valued. (C) After serum starvation, there is no significant difference in the expression level of activated caspase 3.*p-value < 0.05; ns, not significant.
Conclusions
In conclusion, cardiomyopathy associated genetic mutations play an essential role on occurrence of III AVB and HF after RVA pacing in a small proportion of patients. RVA pacing, acting as an extra stimulator, can accelerate the deterioration of cardiac structure and function. Lamin A/C mutations (R216C and L379F) can disrupt nuclear Lamin A/C location and lead to apoptosis of NRCMs after serum starvation. Genetic testing serves as an effective way to identify patients with high risk of HF and pathogenic mechanism of RVA induced cardiomyopathy.

Methods
Study Population. We conducted a retrospective study of AVB patients, who have underwent pacemaker implantation at Fuwai Hospital from January 1987 to December 2013. Enrollment criteria included: III AVB; Baseline left ventricular ejection fraction (LVEF) ≥50%; Single-chamber /dual-chamber pacemaker was implanted with RV lead positioned at RV apical; Repeat echocardiography was available after pacemaker implantation. To assess left ventricular volume and ejection fraction, we used real-time three-dimensional echocardiography (with the iE33 system, Philips) in 86% of the patients, whereas the biplane Simpson's method was used in the other 14%. The echocardiographic images were stored and sent to the core laboratory for analysis by echocardiographic specialists in a blinded fashion. All patients provided written informed consent. Design of this study and informed consent were approved by our local ethics committee (Ethics Committee of Fuwai Hospital affiliated to Peking Union Medical College), and were carried out in accordance with the principles of the Declaration of Helsinki.

RVA associated HF. We reviewed patients' medical records and echocardiography after pacemaker implantation. HF was defined as more than 10% decrease in LVEF with resultant LVEF <50%. Patients who developed HF and identified with an alternative causes of HF such as myocardial infarction, myocardial ischemia on stress testing, severe valvular heart disease, atrial arrhythmias with rapid ventricular response, uncontrolled hypertension and frequent (≥25%) premature ventricular contraction, were excluded. Uncontrolled hypertension was defined as ≥50% of measured blood pressure exceeding 160/100 mmHg according to Framingham Heart Study. In total, 10 patients with RVA pacing associated HF were included in our study. In addition, we included 20 III AVB patients matched for age and gender as the control group.

Mutational analysis. Genomic DNA was extracted from peripheral blood leukocytes using a TIANamp Blood DNA isolation kit (Tiangen, Beijing, China) according to the manufacturer's instructions. The coding and flanking regions of 61 genes associated with inherited arrhythmia and cardiomyopathy were amplified by a custom designed library (Agilent Technologies, Santa Clara, CA, USA) and subsequently sequenced on Genome Analyzer Ix (Illumina Inc, CA, USA). The mutation was confirmed by Sanger's method. Whenever the mutation or single nucleotide polymorphism was found in the proband or her family members, it would be confirmed in 500 unrelated healthy Chinese individuals. A variant was considered as a common polymorphism according to human reference genome (http://www.1000genomes.org/) or Exome Variant Server (http://evs.gs.washington.edu/EVS/). The remaining variants were confirmed by Sanger capillary sequencing and confirmed in 500 unrelated healthy Chinese individuals. A sequence variant was considered to be pathologic if it was absent in 500 ethnically matched healthy controls, and with one of the following criteria: (1) a deletion mutation (2) a missense mutation indicated a damaging effect by anyone of PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.bii.a-star.edu.sg/www/SIFT_BLink_submit.html/) and Mutation_Taster (http://www.mutationtaster.org/). A variant was regarded as Variation of Unknown Significance (VUS) if there were no associated reports and the bioinformatics software produced discrepant results.

Primary culture of neonatal rat cardiomyocytes (NRCMs). Neonatal rat cardiomyocytes were isolated and cultured using the method previously described. The Institutional Animal Care and Use Committee of Fuwai Hospital approved all experimental procedures. All methods were performed in accordance with the relevant guidelines and regulations. Neonatal hearts were placed in an ice-cold Hanks balanced salt solution (HBSS). The apex of the ventricular from the lower 1/3 of the heart was separated and cut into smaller pieces. The pieces were incubated in 1 ml of digestion buffer (0.25 mg Liberase™-TH Research Grade #5401135001 in 10 ml HBSS), and gently stirred at room temperature for 1 minute and then incubated in a 37 °C water bath for 5 min. The digest was collected in 20 ml high glucose DMEM with 10% heat-inactivated Fetal Bovine Serum (FBS). The digestion process was repeated six times. After passing through a 75 μm mesh steel filter 6–8 times, the filtrate was collected and centrifuged at 1200 rpm for 5 min and re-suspended in serum-containing media (10% FBS, 1% penicillin-streptomycin, high glucose DMEM). The cells were pre-plated in 100 mm TC-Treated Culture Dish (Corning, NY, USA) for 1.5 hours to attach non-cardiac cells. After centrifugation and re-suspension in the medium (10% FBS, 1% penicillin-streptomycin, 0.1 mM BrdU, low glucose DMEM), the density of non-attached cells was counted using a haemocytometer and plated into 6-well culture plates or 60mm dishes. After 24 hours, the culture medium was replaced with low glucose DMEM containing 10% FBS.

Construction of lentiviral expression vector containing LAMIN A/C gene. Within the template of Lamin A/C gene, a specific fragment was amplified by PCR. The primers were as follows:

Lamin A/C c.646-MF, AGTGAAGAACCTTGGTGAACCCAGGCGCTG;
Lamin A/C c.646-MR, GCTGTTGCTCTACAGCCTCCTCCTCATGATAT;
Lamin A/C c.1135-MF, GCCCTACCGCAAGTCTCTGGAGGGCAGAGG;
Lamin A/C c.1135-MR, CGCCCTCAAGACCTTGGCGTAGGGCTGAT.
HEK293T cells were seeded into 10-cm culture dish. Transfection were performed with Lipofectamine2000 (Invitrogen) when cells were 90% confluent. Briefly, each dish were transfected with 5μg lentivirus vectors containing the Lamin A/C cDNA (NM_170707.3), 3μg helper plasmid containing Gag/Pol/Rev (Helper 1) and 2μg helper plasmid containing the VSVG envelope. Supernatant were collected 24 hours and 48 hours post transfection. Then the virus were concentrated by ultracentrifugation (Beckman optimal–90K, type 50.2 rotor, 50000 rpm for 4 hours).

**Western blot.** Cells were lysed using radioimmunoprecipitation assay (RIPA) buffer with freshly added protease inhibitor cocktail (Roche, Mannheim, Germany). The cells were scraped off using a cell scraper and incubated on ice for 30 minutes. The lysate was then cleared by centrifuging at 13,000 g at 4°C. Protein concentration was estimated by Enhanced BCA Protein Assay Kit (Beyotime, Beijing, China). 30μg of protein resuspended in Laemmli sample buffer was loaded per sample. Denatured proteins were resolved on 4–12% Nu-PAGE bis-tris polyacrylamide gels and blotted to a polyvinylidene fluoride (PVDF) membrane. Blocking was done with incubation in 10% non-fat dry milk in tris-buffered saline (TBS) with 0.1% Tween-20. The membrane was then probed with primary antibodies in 5% milk in TBST at 4°C overnight and sequentially detected with horseradish peroxidase conjugated secondary antibodies. The signal was revealed by autoradiography using enhanced chemiluminescence (ECL) (Pierce, Thermo Fisher Scientific Inc. Hampshire, UK).

**Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay.** TUNEL assay was performed using In Situ Cell Death Detection Kit, Fluorescein (Roche Applied Sciences, Mannheim, Germany) according to the manufacturer's protocol. Cells were grown on glass coverslips, and after assigned treatment, cells were fixed and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2 minutes on ice. Cells were then incubated in TUNEL reaction mixture at 37°C for 60 minutes in a humidified dark chamber. Coverslips were mounted onto glycerol-based mountant. Images were collected and analyzed on a Zeiss LSM 700 confocal microscope (Carl Zeiss Inc., Germany).

**Immunofluorescence staining.** Cells grown at subconfluency were collected and fixed with 4% paraformaldehyde/phosphate-buffered saline (PBS) and permeabilized with 0.2% Triton X-100 in phosphate-buffered saline for 10 minutes at room temperature. Cells grown at similar subconfluency for all cell lines tested. Primary antibodies in 5% bovine serum albumin in PBS with 0.05% Tween 20 were incubated for 1 hour at room temperature or overnight at 4°C. Cells were washed three times and incubated with appropriate secondary antibodies for 1 hour at room temperature. Slides were mounted in Anti-Fade medium with 4,6-diamidino-2-phenylindole (DAPI) (Zhongshanjinqiao, Beijing, China). Images were collected and analyzed on a Zeiss LSM 700 confocal microscope (Carl Zeiss Inc., Germany). Images were captured using identical exposure times for each cell line.

**Statistical Analysis**

Data are presented as mean ± SD. Significance was compared using SPSS statistical software (version 19.0, SPSS Inc.). Differences between mean values were determined using unpaired or paired Student t-test and ANOVA for multiple comparisons followed by the Bonferroni post-hoc test.

**Data availability.** The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.

**References**

1. Prinzen, F. W. & Peschar, M. Relation between the pacing induced sequence of activation and left ventricular pump function in animals. *Pacing Clin Electrophysiol* **25**, 484–498 (2002).
2. Akerstrom, F. et al. Chronic right ventricular apical pacing: adverse effects and current therapeutic strategies to minimize them. *Ibt J Cardiol* **173**, 351–360, doi:10.1016/j.jcard.2014.03.079 (2014).
3. Wilkoff, B. L. et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. *Jama* **288**, 3115–3123 (2002).
4. Sharma, A. D. et al. Percent right ventricular pacing predicts outcomes in the DAVID trial. *Heart Rhythm* **2**, 830–834, doi:10.1016/j.hrthm.2005.05.015 (2005).
5. Sweeney, M. O. et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. *Circulation* **107**, 2932–2937, doi:10.1161/01.cir.000007269.17295.b1 (2003).
6. Barsheshet, A. et al. Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator. *Heart Rhythm* **8**, 212–218, doi:10.1016/j.hrthm.2010.10.035 (2011).
7. Toff, W. D., Camm, A. J., Skehan, J. D. & United Kingdom, P. & Cardiovascular Events Trial, I. Single-chamber versus dual-chamber pacemaker for sinus node dysfunction. *Circulation* **107**, 2932–2937, doi:10.1161/01.cir.000007269.17295.b1 (2003).
8. Zhang, X. H. et al. Longer paced QRS duration is associated With increased prevalence of Right Ventricular Pacing-Induced Cardiomyopathy. *J Cardiovasc Electrophysiol* **27**, 1174–1179, doi:10.1111/jce.13045 (2016).
9. Khurshid, S. et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. *Heart Rhythm* **11**, 1619–1625, doi:10.1016/j.hrthm.2014.05.040 (2014).
10. Krebs, B. O., Moller, R. N., Rasmussen, A. K., Mortensen, J. & Nyboe, T. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. *Heart Rhythm* **11**, 1619–1625, doi:10.1016/j.hrthm.2014.05.040 (2014).
11. Khurshid, S. et al. Longer Paced QRS Duration is Associated With Increased Prevalence of Right Ventricular Pacing-Induced Cardiomyopathy. *J Cardiovasc Electrophysiol* **27**, 1174–1179, doi:10.1111/jce.13045 (2016).
12. Dreger, H., Maethner, K., Bondke, H., Baumann, G. & Melzer, C. Pacing-induced cardiomyopathy in patients with right ventricular stimulation for >15 years. *Europace* **14**, 238–242, doi:10.1093/europace/eur258 (2012).
13. Dreger, H., Maethner, K., Bondke, H., Baumann, G. & Melzer, C. Pacing-induced cardiomyopathy in patients with right ventricular stimulation for >15 years. *Circulation* **14**, 238–242, doi:10.1093/europace/eur258 (2012).
14. Khurshid, S. et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. *Heart Rhythm* **11**, 1619–1625, doi:10.1016/j.hrthm.2014.05.040 (2014).
15. Khurshid, S. et al. Longer Paced QRS Duration is Associated With Increased Prevalence of Right Ventricular Pacing-Induced Cardiomyopathy. *J Cardiovasc Electrophysiol* **27**, 1174–1179, doi:10.1111/jce.13045 (2016).
16. Khurshid, S. et al. Longer Paced QRS Duration is Associated With Increased Prevalence of Right Ventricular Pacing-Induced Cardiomyopathy. *J Cardiovasc Electrophysiol* **27**, 1174–1179, doi:10.1111/jce.13045 (2016).
17. Dreger, H., Maethner, K., Bondke, H., Baumann, G. & Melzer, C. Pacing-induced cardiomyopathy in patients with right ventricular stimulation for >15 years. *Europace* **14**, 238–242, doi:10.1093/europace/eur258 (2012).
14. Ebert, M. et al. Long-Term Impact of Right Ventricular Pacing on Left Ventricular Systolic Function in Pacemaker Recipients With Preserved Ejection Fraction: Results From a Large Single-Center Registry. Journal of the American Heart Association 5, e003485, doi:10.1161/JAHA.116.003485 (2016).

15. Skrzynia, C., Berg, J. S., Willis, M. S. & Jensen, B. C. Genetics and heart failure: a concise guide for the clinician. Current cardiology reviews 11, 10–17 (2015).

16. Haas, J. et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J, doi:10.1093/eurheartj/ehu301 (2014).

17. Pasotti, M. et al. Long-term outcome and risk stratification in dilated cardiomyopathies. J Am Coll Cardiol 52, 1250–1260, doi:10.1016/j.jacc.2008.06.044 (2008).

18. Fatkin, D. et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341, 1715–1724, doi:10.1056/nejm199912023412302 (1999).

19. Pan, H. et al. A novel mutation in LAMIN A/C is associated with isolated early-onset atrial fibrillation and progressive atrioventricular block followed by cardiomyopathy and sudden cardiac death. Heart Rhythm 6, 707–710, doi:10.1016/j.hrthm.2009.01.037 (2009).

20. Lamas, G. A. et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 346, 1854–1862, doi:10.1056/NEJMoa0301304 (2002).

21. Nielsen, J. C. et al. A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: echocardiographic and clinical outcome. J Am Coll Cardiol 42, 614–623 (2003).

22. Andersen, H. R. et al. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 350, 1210–1216, doi:10.1016/s0140-6736(97)03425-9 (1997).

23. Nielsen, J. C. et al. A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome. Eur Heart J 32, 686–696, doi:10.1093/eurheartj/eho222 (2011).

24. Sweeney, M. O. & Hellkamp, A. S. Heart failure during cardiac pacing. Circulation 113, 2082–2088, doi:10.1161/CIRCULATIONAHA.105.608356 (2004).

25. Tse, H. F. et al. Functional abnormalities in patients with permanent right ventricular pacing: the effect of sites of electrical stimulation. J Am Coll Cardiol 40, 1451–1458 (2002).

26. Tse, H. F. & Lau, C. P. Long-term effect of right ventricular pacing on myocardial perfusion and function. J Am Coll Cardiol 29, 744–749 (1997).

27. Curtis, A. B. et al. Biventricular pacing for atrioventricular block and systolic dysfunction. The New England journal of medicine 368(17), 1585–1593, doi:10.1056/NEJMoai1210536 (2013).

28. Mizukami, A. et al. Implications of right ventricular septal pacing for medium-term prognosis: Propensity-matched analysis. International journal of cardiology 220, 214–218, doi:10.1016/j.ijcard.2016.06.230 (2016).

29. Wolf, C. M. et al. Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. J Mol Cell Cardiol 44, 293–303, doi:10.1016/j.yjmcc.2007.11.008 (2008).

30. Pugh, T. J. et al. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med 16, 601–608, doi:10.1038/gim.2013.204 (2014).

31. Ananthakrishnan, R., Moe, G. W., Goldenhal, M. J. & Marin-Garcia, J. Akt signaling pathway in pacing-induced heart failure. Mol Cell Biochem 268, 103–110 (2005).

32. Hanna, N., Cardin, S., Leung, T. K. & Nattel, S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 63, 236–244, doi:10.1016/j.jdrc.2004.03.026 (2004).

33. Schulz, R. et al. Stress kinase phosphorylation is increased in pacing-induced heart failure in rabbits. Am J Physiol Heart Circ Physiol 285, H2084–2090, doi:10.1152/ajpheart.01038.2002 (2003).

34. Kuramochi, Y., Guo, X., Sawyer, D. B. & Lim, C. C. Rapid electrical stimulation induces early activation of kinase signal transduction pathways and apoptosis in adult rat ventricular myocytes. Exp Physiol 91, 773–780, doi:10.1113/expphysiol.2006.033894 (2006).

35. Siu, C. W. et al. Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. Aging (Albany NY) 4, 803–822 (2012).

36. Muchir, A., Shan, J., Bonne, G., Lehnart, S. E. & Worman, H. J. Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins. Hum Mol Genet 18, 241–247, doi:10.1093/hmg/ddn343 (2009).

37. Muchir, A., Wu, W. & Worman, H. J. Mitogen-activated protein kinase inhibitor regulation of heart function and fibrosis in cardiomyopathy caused by lamin A/C gene mutation. Trends Cardiovasc Med 20, 217–221, doi:10.1016/j.tcm.2011.11.002 (2010).

38. Muchir, A., Wu, W., Sera, F., Homma, S. & Worman, H. J. Mitogen-activated protein kinase kinase 1/2 converting inhibition in mice with cardiomyopathy caused by lamin A/C gene mutation. Biochem Biophys Res Commun 452, 958–961, doi:10.1016/j.bbrc.2014.09.020 (2014).

39. Vatta, M. et al. Molecular and clinical characterization of a novel SCN5A mutation associated with isolated early-onset atrial fibrillation and progressive Brugada syndrome. Hum Mol Genet 11, 337–345 (2002).

40. Wang, Q. et al. The common SCNSA mutation R1193Q causes LQTS-type electrophysiological alterations of the cardiac sodium channel. J Med Genet 41, e66 (2004).

41. Hwang, H. W. et al. R1193Q of SCN5A, a Brugada and long QT mutation, is a common polymorphism in Han Chinese. J Med Genet 42, e7, author reply e8, 803–812 (2005).

42. Sun, A. et al. SCN5A R1193Q polymorphism associated with progressive cardiac conduction defects and long QT syndrome in a Chinese family. J Med Genet 45, 127–128, doi:10.1136/jmg.2007.056333 (2008).

43. Siu, D. M. et al. A common SCN5A polymorphism attenuates a severe cardiac phenotype caused by a nonsense SCN5A mutation in a Chinese family with an inherited cardiac conduction defect. J Med Genet 43, 817–821, doi:10.1136/jmg.2006.042192 (2006).

44. Albertsen, A. E. et al. Adverse effect of right ventricular pacing prevented by biventricular pacing during long-term follow-up: a randomized comparison. Eur J Echocardiogr 12, 767–772, doi:10.1093/ejechocard/jer136 (2011).

45. Ge, J. et al. Molecular and clinical characterization of a novel SCN5A mutation associated with atrioventricular block and dilated cardiomyopathy. Circulation Arrhythmia and electrophysiology. 1(2), 83–92, doi:10.1161/cirarr.107.0750752 (2008).

46. Fonseca, C. et al. The diagnosis of heart failure in primary care: value of symptoms and signs. Eur J Heart Fail. 8(6):795–800–812–2. doi:10.1016/j.eurhcf.2006.07.002 (2004).

47. Lloyd-Jones, D. M. et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106, 3068–3073 (2002).

48. Franke, W. W. et al. The area concomitats of adhering junctions connecting heart muscle cells of vertebrates - III: assembly and disintegration of intercalated disks in rat cardiomyocytes growing in culture. Eur J Cell Biol 86, 127–142, doi:10.1016/j.ejcb.2006.11.003 (2007).

49. Cholewa, B. D., Pellitteri-Hahn, M. C., Scarlett, C. O. & Ahmad, N. Large-scale label-free comparative proteomics analysis of polypeptide kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells. J Proteome Res 13, 5041–5050, doi:10.1021/pr5002516 (2014).
Acknowledgements
We are very grateful to all patients and their family for permission to join our study. This work is partly supported by National Natural Scientific Foundation of China (81470460 to J.P.).

Author Contributions
Liu Nn. participated in conception and design, acquisition of data and drafting and revising the manuscript; Zheng M. took part in acquisition of data and analysis of data; Li Sj. carried out acquisition of data and statistical analysis; Bai H. took part in acquisition of data; Liu Zy. participated in revision of the article; Hou Ch. took part in acquisition of data and analysis of data; Zhang S. took part in the final approval of the version to be published; Pu Jl. took part in applying for examination of ethics and interpretation of data, carrying out design, having given final approval of the version to be published. All the authors has read and approved the final manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-11211-2

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017